Vanguard Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $13.3B | Buy |
139,685,997
+1,436,550
| +1% | +$141M | 0.19% | 88 |
|
|
2025
Q3 | $13.5B | Buy |
138,249,447
+1,115,337
| +0.8% | +$116M | 0.2% | 85 |
|
|
2025
Q2 | $14.7B | Buy |
137,134,110
+2,545,381
| +2% | +$258M | 0.24% | 63 |
|
|
2025
Q1 | $13.6B | Buy |
134,588,729
+1,697,945
| +1% | +$171M | 0.25% | 68 |
|
|
2024
Q4 | $11.9B | Buy |
132,890,784
+1,600,062
| +1% | +$141M | 0.21% | 79 |
|
|
2024
Q3 | $11B | Buy |
131,290,722
+1,420,249
| +1% | +$112M | 0.2% | 85 |
|
|
2024
Q2 | $10B | Buy |
129,870,473
+2,432,589
| +2% | +$178M | 0.19% | 88 |
|
|
2024
Q1 | $8.73B | Buy |
127,437,884
+1,988,082
| +2% | +$128M | 0.17% | 102 |
|
|
2023
Q4 | $7.25B | Buy |
125,449,802
+1,681,454
| +1% | +$89.8M | 0.16% | 108 |
|
|
2023
Q3 | $6.53B | Buy |
123,768,348
+1,525,432
| +1% | +$80M | 0.16% | 109 |
|
|
2023
Q2 | $6.61B | Buy |
122,242,916
+1,999,170
| +2% | +$104M | 0.16% | 106 |
|
|
2023
Q1 | $6.02B | Buy |
120,243,746
+1,469,952
| +1% | +$69.3M | 0.15% | 117 |
|
|
2022
Q4 | $5.5B | Buy |
118,773,794
+1,887,558
| +2% | +$81.7M | 0.15% | 124 |
|
|
2022
Q3 | $4.53B | Buy |
116,886,236
+1,708,496
| +1% | +$68.5M | 0.13% | 141 |
|
|
2022
Q2 | $4.29B | Buy |
115,177,740
+1,812,913
| +2% | +$73.8M | 0.12% | 155 |
|
|
2022
Q1 | $5.02B | Buy |
113,364,827
+1,743,197
| +2% | +$75.5M | 0.12% | 154 |
|
|
2021
Q4 | $4.74B | Buy |
111,621,630
+408,827
| +0.4% | +$17.2M | 0.11% | 176 |
|
|
2021
Q3 | $4.83B | Buy |
111,212,803
+1,077,710
| +1% | +$47.7M | 0.12% | 147 |
|
|
2021
Q2 | $4.71B | Buy |
110,135,093
+305,405
| +0.3% | +$12.8M | 0.12% | 149 |
|
|
2021
Q1 | $4.24B | Sell |
109,829,688
-951,470
| -0.9% | -$36M | 0.11% | 150 |
|
|
2020
Q4 | $3.98B | Sell |
110,781,158
-1,224,828
| -1% | -$44.1M | 0.12% | 153 |
|
|
2020
Q3 | $4.28B | Sell |
112,005,986
-1,114,056
| -1% | -$42.9M | 0.14% | 123 |
|
|
2020
Q2 | $3.97B | Buy |
113,120,042
+1,393,290
| +1% | +$50.2M | 0.14% | 129 |
|
|
2020
Q1 | $3.65B | Buy |
111,726,752
+2,709,903
| +2% | +$106M | 0.16% | 118 |
|
|
2019
Q4 | $4.93B | Buy |
109,016,849
+913,742
| +0.8% | +$38.2M | 0.17% | 107 |
|
|
2019
Q3 | $4.4B | Buy |
108,103,107
+1,231,208
| +1% | +$52.2M | 0.16% | 113 |
|
|
2019
Q2 | $4.59B | Buy |
106,871,899
+1,649,632
| +2% | +$63.5M | 0.17% | 101 |
|
|
2019
Q1 | $4.04B | Buy |
105,222,267
+1,381,019
| +1% | +$52.7M | 0.16% | 111 |
|
|
2018
Q4 | $3.67B | Buy |
103,841,248
+2,387,890
| +2% | +$86.6M | 0.16% | 105 |
|
|
2018
Q3 | $3.91B | Buy |
101,453,358
+1,367,053
| +1% | +$47.7M | 0.15% | 117 |
|
|
2018
Q2 | $3.27B | Buy |
100,086,305
+1,576,173
| +2% | +$47.5M | 0.14% | 131 |
|
|
2018
Q1 | $2.69B | Buy |
98,510,132
+1,830,157
| +2% | +$49.7M | 0.12% | 172 |
|
|
2017
Q4 | $2.4B | Buy |
96,679,975
+1,442,815
| +2% | +$39.8M | 0.1% | 193 |
|
|
2017
Q3 | $2.78B | Buy |
95,237,160
+1,579,860
| +2% | +$43.6M | 0.13% | 141 |
|
|
2017
Q2 | $2.6B | Buy |
93,657,300
+2,522,556
| +3% | +$66.9M | 0.13% | 149 |
|
|
2017
Q1 | $2.27B | Buy |
91,134,744
+3,503,965
| +4% | +$85.2M | 0.12% | 168 |
|
|
2016
Q4 | $1.9B | Buy |
87,630,779
+1,802,661
| +2% | +$39.3M | 0.11% | 187 |
|
|
2016
Q3 | $2.04B | Buy |
85,828,118
+3,065,345
| +4% | +$73.1M | 0.12% | 164 |
|
|
2016
Q2 | $1.93B | Sell |
82,762,773
-15,437,741
| -16% | -$334M | 0.12% | 169 |
|
|
2016
Q1 | $1.85B | Buy |
98,200,514
+3,263,402
| +3% | +$57.3M | 0.12% | 163 |
|
|
2015
Q4 | $1.75B | Buy |
94,937,112
+2,753,185
| +3% | +$49.3M | 0.12% | 164 |
|
|
2015
Q3 | $1.51B | Buy |
92,183,927
+2,399,761
| +3% | +$41M | 0.11% | 180 |
|
|
2015
Q2 | $1.59B | Sell |
89,784,166
-13,609,498
| -13% | -$243M | 0.11% | 188 |
|
|
2015
Q1 | $1.84B | Buy |
103,393,664
+1,694,252
| +2% | +$26.8M | 0.12% | 162 |
|
|
2014
Q4 | $1.35B | Buy |
101,699,412
+3,979,591
| +4% | +$50.9M | 0.1% | 218 |
|
|
2014
Q3 | $1.15B | Buy |
97,719,821
+2,310,917
| +2% | +$29.1M | 0.09% | 235 |
|
|
2014
Q2 | $1.22B | Buy |
95,408,904
+3,182,718
| +3% | +$41.4M | 0.1% | 217 |
|
|
2014
Q1 | $1.25B | Buy |
92,226,186
+2,567,778
| +3% | +$33.7M | 0.1% | 195 |
|
|
2013
Q4 | $1.08B | Buy |
89,658,408
+2,636,953
| +3% | +$31.2M | 0.09% | 221 |
|
|
2013
Q3 | $1.02B | Buy |
87,021,455
+2,476,318
| +3% | +$26.8M | 0.1% | 202 |
|
|
2013
Q2 | $784M | Buy |
+84,545,137
| New | +$717M | 0.08% | 263 |
|
Other funds holding BSX
Vanguard Group's BSX Position: Q4 2025 in Review
Vanguard Group increased its Boston Scientific (BSX) stake by 1% in Q4 2025, buying an estimated $141M and bringing the position to 139,685,997 shares worth $13.3B. The position accounts for 0.19% of the portfolio, ranked #88.
Vanguard Group first reported a position in BSX in Q2 2013 and has held it in 51 quarters since. The position peaked at $14.7B in Q2 2025. 1,790 funds tracked by Wall St. Rank hold BSX as of Q4 2025.
- Vanguard Group held 139,685,997 shares of Boston Scientific worth $13.3B as of Q4 2025.
- Vanguard Group bought 1,436,550 Boston Scientific shares in Q4 2025, an estimated $141M.
- Boston Scientific made up 0.19% of Vanguard Group's portfolio in Q4 2025, its #88 holding.
- Vanguard Group first reported a position in Boston Scientific in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Boston Scientific position peaked at $14.7B in Q2 2025.
- 1,790 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.